Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib

Medical Oncology

Volumn 28, Issue 1, 2011, Pages 331-335

  Wang, Fenghua ^a   Zhang, Yang ^a   Zhao, Hongyun ^a   Chen, Likun ^a   Shi, Yan Xia ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Erlotinib; Gefitinib; Non small cell lung cancer; Prognostic model

Indexed keywords

GEFITINIB; LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CHINESE; CLINICAL TRIAL; GENE DOSAGE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; TREATMENT DURATION; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; QUINAZOLINES; RETROSPECTIVE STUDIES;

EID: 79952252124     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-010-9451-1     Document Type: Article

References (19)

1. A Jemal R Siegel E Ward T Murray J Xu, et al. 2007 Cancer statistics, 2007 Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 (Pubitemid 46148091)
2. MQ Baggstrom TE Stinchcombe DB Fried C Poole TA Hensing, et al. 2007 Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis J Thorac Oncol 2 845 853 17805063 10.1097/JTO.0b013e31814617a2 (Pubitemid 47361027)
3. FA Shepherd J Dancey R Ramlau K Mattson R Gralla, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 10811675 1:CAS:528:DC%2BD3cXktVyjsLc%3D (Pubitemid 30324363)
4. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 16014882 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
5. N Thatcher A Chang P Parikh JR Pereira T Ciuleanu 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer, ISEL study) Lancet 366 1527 1537 16257339 10.1016/S0140-6736(05)67625-8 1:CAS:528: DC%2BD2MXhtFKhsbfP (Pubitemid 41540110)
6. GM Clark DM Zborowski P Santabarbara K Ding M Whitehead, et al. 2006 Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21 Clin Lung Cancer 7 389 394 16800964 10.3816/CLC.2006.n.022 1:CAS:528: DC%2BD28XmsFyqt7c%3D (Pubitemid 44043548)
7. T Cufer E Vrdoljak R Gaafar I Erensoy K Pemberton 2006 SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer Anticancer Drugs 17 401 409 16549997 10.1097/01.cad.0000203381.99490.ab 1:CAS:528:DC%2BD28Xis1Sis7c%3D (Pubitemid 44309982)
8. R Maruyama Y Nishiwaki T Tamura N Yamamoto M Tsuboi, et al. 2008 Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J Clin Oncol 26 4244 4252 18779611 10.1200/JCO.2007.15.0185 1:CAS:528:DC%2BD1cXhtF2it7bK
9. ES Kim V Hirsh T Mok MA Socinski R Gervais, et al. 2008 Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 1809 1818 19027483 10.1016/S0140-6736(08) 61758-4 1:CAS:528:DC%2BD1cXhsVWhtbjM
10. M Florescu B Hasan L Seymour K Ding FA Shepherd 2008 National Cancer Institute of Canada Clinical Trials Group. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21 J Thorac Oncol 3 590 598 18520796 10.1097/JTO. 0b013e3181729299 (Pubitemid 351787301)
11. ZZ Guan L Zhang LY Li GL Jiang XY Liu, et al. 2005 Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial Ai Zheng 24 980 984 16086877 Article in Chinese
12. MJ Park J Lee JY Hong MK Choi JH Yi, et al. 2009 Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment Cancer 115 1518 1530 19177485 10.1002/cncr.24151 1:CAS:528:DC%2BD1MXksF2qs7o%3D
13. M Satouchi S Negoro Y Funada Y Urata T Shimada, et al. 2007 Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib Br J Cancer 96 1191 1196 17387341 10.1038/sj.bjc.6603710 1:CAS:528:DC%2BD2sXkt1GqtL0%3D (Pubitemid 46625078)
14. SW Han TY Kim PG Hwang S Jeong J Kim, et al. 2005 Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2493 2501 15710947 10.1200/JCO.2005.01.388 1:CAS:528:DC%2BD2MXjvVyktL0%3D (Pubitemid 47050839)
15. T Mitsudomi T Kosaka H Endoh Y Horio T Hida, et al. 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence J Clin Oncol 23 2513 2520 15738541 10.1200/JCO.2005.00. 992 1:CAS:528:DC%2BD2MXjvVyktLs%3D (Pubitemid 47050841)
16. F Cappuzzo FR Hirsch E Rossi S Bartolini GL Ceresoli, et al. 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643 655 15870435 10.1093/jnci/dji112 1:CAS:528:DC%2BD2MXjvFymt70%3D (Pubitemid 40812628)
17. DA Eberhard BE Johnson LC Amler AD Goddard SL Heldens, et al. 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall- cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 5900 5909 16043828 10.1200/JCO.2005.02.857 1:CAS:528:DC%2BD2MXhtVKgtbzO
18. E Massarelli M Varella-Garcia X Tang AC Xavier NC Ozburn, et al. 2007 KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Cancer Res 13 2890 2896 17504988 10.1158/1078-0432.CCR-06-3043 1:CAS:528:DC%2BD2sXlt1Krs7g%3D (Pubitemid 46849563)
19. TS Mok YL Wu S Thongprasert CH Yang DT Chu, et al. 2009 Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma N Engl J Med 361 947 957 19692680 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK